Bio-Techne Investors Website

Where Science Intersects Innovation™

As Bio-Techne, we have united multiple brands to provide a unique and comprehensive product portfolio. Together, our brands provide world class products and services for life-science research and clinical applications.

Investor Presentation

Latest Presentation

September 8, 2023

2023 Investor Day Presentation

View Presentation View All

71.3%

Adjusted Gross Margin of 71.3%

$0.41

Adjusted EPS of $0.41

$276.9

Revenue of $276.9 million

Sign up for E-Mail Alerts

Sign up today

Stock Information

Bio-Techne Corporation

Nasdaq: TECH

 |  View Detailed Stock Info

Price
Change
Volume
Day Range
52 Week Range

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx® Prostate test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 Billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide.

Fast Facts

Net Sales (July 2022 to June 2023)

$1.1 Billion

Employees Worldwide

~3,200

Products

500,000+

Journal citations

350,000+

Incorporated in Minneapolis, Minnesota

1981

Leadership

Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is a source of our success.

IR Contact Information

Company Information

Corporate Secretary
614 McKinley Place NE
Minneapolis, MN 55413

Investor Relations

David Clair
T: 612-656-4416
ir@bio-techne.com

Transfer Agent

American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
help@astfinancial.com